Acarix Appoints Helen Ljungdahl Round as Head of New US Subsidiary

Acarix has appointed Helen Ljungdahl Round as head of the company’s newly established US subsidiary Acarix Inc. Round will assume her position in September 2021 and build the US organization. She will be a member of Acarix AB’s Executive Management Group.
 
Acarix is a leader in AI driven diagnostics for immediate rule-out of coronary artery disease. The US Food and Drug Administration (FDA) has granted Acarix De Novo clearance for its CADScor System, which is an easy-to-use, rapid and non-invasive test that can be performed in both in- and out-patient settings. It has the potential to play a major role in securing timely and efficient evaluation and rule-out of patients with stable coronary artery disease.

Round has more than 25 years of experience from executive and global positions in the pharmaceutical industry with Merck & Co, Inc (MSD) and as senior vice president global marketing & business development for GN Hearing. Her most recent position was CEO of Amnicell, a biotech start-up company based in New York City. Round has spent most of her professional life in the US, where she has worked for American companies, and held Board and Advisory assignments. She is recognized as a strong commercial leader who builds high performing teams and organizations to delivered profitable and sustainable business results.
 
Per Persson, CEO of Acarix, commented, “We are delighted to have recruited Helen to lead our new US operations in this intense and exciting phase for Acarix. Helen has a wealth of experience in global sales and marketing in health technology and the pharmaceutical sector. Her background and experience provide us with the right leadership to successfully drive sales of CADScor System and establish Acarix in the North American market.”
 
Round said, “Coronary artery disease affects 18 million adults and causes more than 365,000 deaths annually in the USA. The CADScor System holds significant future potential in the rapid assessment and rule-out of coronary artery disease. I am looking forward to bringing CADScor System to the US market and contributing to the health and wellness of patients with heart disease.”